Genetic Engineered Preparations - An Innovative Approach in the Treatment of Rheumatoid Arthritis

Abstract

Currently, there are at least 20 genetically engineered drugs with different mechanisms of action used in the treatment of RA, and their number continues to increase every year. The use of genetically engineered drugs at an early stage of RA is of great importance, i.e. before the development of bone changes. In these cases, it is possible to develop remission for an indefinite period, which is tantamount to recovery. This paper provides information on the effectiveness of the use of genetically engineered drugs: rituximab, tocilizumab, alalimumab, infliximab in rheumatoid arthritis. Information on contraindications, method of administration, possible use during pregnancy and early rheumatoid arthritis is indicated.